Academic Cancer Care
Ironwood Cancer & Research Centers are committed to the advancement of medical knowledge and patient care. Medical research has and continues to transform the practice of medicine resulting in a high quality of care we enjoy today. We believe that by supporting clinical research today, we are helping build the future of medicine and the profound developments that are sure to come. We have an active and expanding clinical research program.
We have a comprehensive team of physician investigators, research nurses, clinical research coordinators, research assistants and regulatory specialist serving all our offices. This allows us to provide the option for our eligible patients to the latest therapies and treatments. If you are interested in participating in a clinical trial, please talk to your physician or call our research department at 480-398-7671. Learn more about participating in a clinical trial here.
Current Studies at Ironwood Cancer & Research Centers
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Protocol number MK2870-010
Sponsor Merck Sharp & Dohme LLC
Pro00075309 American Society of Clinical Oncology (ASCO)
Sponsor American Society of Clinical Oncology
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
Protocol number AMG 20210081
Sponsor Amgen
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON)
Protocol number Janssen_COCOON
Sponsor Janssen Research & Development, LLC
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Protocol number MK-2870-012
Sponsor Merck Sharp & Dohme LLC
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)
Protocol number D8531C00002
Sponsor Astra Zeneca
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)
Protocol number 02-MX-003
Sponsor Guardant Health, Inc.
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Protocol number PM1183-C-008-21
Sponsor PharmaMar
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)
Protocol number DS1062-A-U304
Sponsor Daiichi-Sankyo
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Protocol number DS1062-A-U303
Sponsor Daiichi-Sankyo
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)
Protocol number PACIFIC-8 D9075C00001
Sponsor Astra Zeneca
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Protocol number SGNDV-005
Sponsor Seagen Inc.
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC
Protocol number M18-868
Sponsor AbbVie
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
Protocol number LP-CT-PALO-202101
Sponsor Xiamen LP Pharmaceutical Co., Ltd
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents (EvoPAR-PR01)
Protocol number D973C00001
Sponsor Astra Zeneca
